Switch theme
Sign up to access all valuation multiples
Sichuan Biokin Pharmaceutical Co Ltd is a chemical drug and biological drug-based company that integrates drug research and development, production and marketing.
2006
n/a
LTM Revenue $661M
LTM EBITDA $371M
$13.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sichuan Biokin has a last 12-month revenue of $661M and a last 12-month EBITDA of $371M.
In the most recent fiscal year, Sichuan Biokin achieved revenue of $802M and an EBITDA of $565M.
Sichuan Biokin expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sichuan Biokin valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $77.4M | $802M | XXX | XXX | XXX |
| Gross Profit | $64.8M | $45.8M | XXX | XXX | XXX |
| Gross Margin | 84% | 6% | XXX | XXX | XXX |
| EBITDA | -$93.6M | $565M | XXX | XXX | XXX |
| EBITDA Margin | -121% | 70% | XXX | XXX | XXX |
| Net Profit | -$38.9M | -$108M | XXX | XXX | XXX |
| Net Margin | -50% | -13% | XXX | XXX | XXX |
| Net Debt | n/a | $7.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Sichuan Biokin's stock price is CNY 240 (or $33).
Sichuan Biokin has current market cap of CNY 96.3B (or $13.3B), and EV of CNY 95.1B (or $13.1B).
See Sichuan Biokin trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13.1B | $13.3B | XXX | XXX | XXX | XXX | $0.92 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Sichuan Biokin has market cap of $13.3B and EV of $13.1B.
Sichuan Biokin's trades at 19.8x LTM EV/Revenue multiple, and 35.3x LTM EBITDA.
Analysts estimate Sichuan Biokin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sichuan Biokin and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $13.1B | XXX | XXX | XXX |
| EV/Revenue | 16.3x | XXX | XXX | XXX |
| EV/EBITDA | 23.2x | XXX | XXX | XXX |
| P/E | 26.0x | XXX | XXX | XXX |
| P/E/Growth | -0.3x | XXX | XXX | XXX |
| EV/FCF | 23.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSichuan Biokin's NTM/LTM revenue growth is -52%
Sichuan Biokin's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Sichuan Biokin's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sichuan Biokin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sichuan Biokin and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 936% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 70% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -703% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 18% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 25% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 31% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sichuan Biokin acquired XXX companies to date.
Last acquisition by Sichuan Biokin was XXXXXXXX, XXXXX XXXXX XXXXXX . Sichuan Biokin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Sichuan Biokin founded? | Sichuan Biokin was founded in 2006. |
| Where is Sichuan Biokin headquartered? | Sichuan Biokin is headquartered in China. |
| Is Sichuan Biokin publicy listed? | Yes, Sichuan Biokin is a public company listed on SHG. |
| What is the stock symbol of Sichuan Biokin? | Sichuan Biokin trades under 688506 ticker. |
| When did Sichuan Biokin go public? | Sichuan Biokin went public in 2023. |
| Who are competitors of Sichuan Biokin? | Similar companies to Sichuan Biokin include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Sichuan Biokin? | Sichuan Biokin's current market cap is $13.3B |
| What is the current revenue of Sichuan Biokin? | Sichuan Biokin's last 12-month revenue is $661M. |
| What is the current EBITDA of Sichuan Biokin? | Sichuan Biokin's last 12-month EBITDA is $371M. |
| What is the current EV/Revenue multiple of Sichuan Biokin? | Current revenue multiple of Sichuan Biokin is 19.8x. |
| What is the current EV/EBITDA multiple of Sichuan Biokin? | Current EBITDA multiple of Sichuan Biokin is 35.3x. |
| What is the current revenue growth of Sichuan Biokin? | Sichuan Biokin revenue growth between 2023 and 2024 was 936%. |
| Is Sichuan Biokin profitable? | Yes, Sichuan Biokin is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
